The incidence and prognosis of osteosarcoma skip metastases

Kaveh R. Sajadi, Robert Heck, Michael D. Neel, Bhaskar N. Rao, Najat Daw, Carlos Rodriguez-Galindo, Fredric A. Hoffer, G. Scott Stacy, Terrance D. Peabody, Michael A. Simon

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The poor prognosis for patients with osteosarcoma skip metastases has been established in the literature; however, most of the data in the literature concerning osteosarcoma skip metastases were collected before routine use of magnetic resonance imaging and before the use of modern multiagent chemotherapy regimens. This retrospective multiinstitutional study was done to evaluate the efficacy of magnetic resonance imaging to detect skip metastases and to evaluate the prognosis for these patients when treated with modern multiagent chemotherapy protocols. In a group of 155 patients who were younger than 26 years when diagnosed and treated for high-grade osteosarcoma of the long bones, 10 (6.5%) patients with skip metastases were identified. Eight of the 10 lesions were detected on pretreatment magnetic resonance imaging scans and two were detected only from the surgical pathology specimens. Five patients had concomitant pulmonary metastases at presentation and five patients had no other known site of diseases. All 10 patients died, with an average survival of 32.5 months (range 11-71 months). The five patients with only skip metastases at presentation survived an average of 27.2 months (range 15-44 months). Despite advances in the treatment of patients with osteosarcomas, those with skip metastases continue to have a poor prognosis, and they should be counseled regarding the limitations of current therapies.

Original languageEnglish (US)
Pages (from-to)92-96
Number of pages5
JournalClinical Orthopaedics and Related Research
Issue number426
DOIs
StatePublished - Jan 1 2004

Fingerprint

Osteosarcoma
Neoplasm Metastasis
Incidence
Magnetic Resonance Imaging
Drug Therapy
Surgical Pathology
Retrospective Studies
Bone and Bones
Lung
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Sajadi, K. R., Heck, R., Neel, M. D., Rao, B. N., Daw, N., Rodriguez-Galindo, C., ... Simon, M. A. (2004). The incidence and prognosis of osteosarcoma skip metastases. Clinical Orthopaedics and Related Research, (426), 92-96. https://doi.org/10.1097/01.blo.0000141493.52166.69

The incidence and prognosis of osteosarcoma skip metastases. / Sajadi, Kaveh R.; Heck, Robert; Neel, Michael D.; Rao, Bhaskar N.; Daw, Najat; Rodriguez-Galindo, Carlos; Hoffer, Fredric A.; Stacy, G. Scott; Peabody, Terrance D.; Simon, Michael A.

In: Clinical Orthopaedics and Related Research, No. 426, 01.01.2004, p. 92-96.

Research output: Contribution to journalArticle

Sajadi, KR, Heck, R, Neel, MD, Rao, BN, Daw, N, Rodriguez-Galindo, C, Hoffer, FA, Stacy, GS, Peabody, TD & Simon, MA 2004, 'The incidence and prognosis of osteosarcoma skip metastases', Clinical Orthopaedics and Related Research, no. 426, pp. 92-96. https://doi.org/10.1097/01.blo.0000141493.52166.69
Sajadi, Kaveh R. ; Heck, Robert ; Neel, Michael D. ; Rao, Bhaskar N. ; Daw, Najat ; Rodriguez-Galindo, Carlos ; Hoffer, Fredric A. ; Stacy, G. Scott ; Peabody, Terrance D. ; Simon, Michael A. / The incidence and prognosis of osteosarcoma skip metastases. In: Clinical Orthopaedics and Related Research. 2004 ; No. 426. pp. 92-96.
@article{0eca5d1346ae4a168d7b9e16014255ea,
title = "The incidence and prognosis of osteosarcoma skip metastases",
abstract = "The poor prognosis for patients with osteosarcoma skip metastases has been established in the literature; however, most of the data in the literature concerning osteosarcoma skip metastases were collected before routine use of magnetic resonance imaging and before the use of modern multiagent chemotherapy regimens. This retrospective multiinstitutional study was done to evaluate the efficacy of magnetic resonance imaging to detect skip metastases and to evaluate the prognosis for these patients when treated with modern multiagent chemotherapy protocols. In a group of 155 patients who were younger than 26 years when diagnosed and treated for high-grade osteosarcoma of the long bones, 10 (6.5{\%}) patients with skip metastases were identified. Eight of the 10 lesions were detected on pretreatment magnetic resonance imaging scans and two were detected only from the surgical pathology specimens. Five patients had concomitant pulmonary metastases at presentation and five patients had no other known site of diseases. All 10 patients died, with an average survival of 32.5 months (range 11-71 months). The five patients with only skip metastases at presentation survived an average of 27.2 months (range 15-44 months). Despite advances in the treatment of patients with osteosarcomas, those with skip metastases continue to have a poor prognosis, and they should be counseled regarding the limitations of current therapies.",
author = "Sajadi, {Kaveh R.} and Robert Heck and Neel, {Michael D.} and Rao, {Bhaskar N.} and Najat Daw and Carlos Rodriguez-Galindo and Hoffer, {Fredric A.} and Stacy, {G. Scott} and Peabody, {Terrance D.} and Simon, {Michael A.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/01.blo.0000141493.52166.69",
language = "English (US)",
pages = "92--96",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "426",

}

TY - JOUR

T1 - The incidence and prognosis of osteosarcoma skip metastases

AU - Sajadi, Kaveh R.

AU - Heck, Robert

AU - Neel, Michael D.

AU - Rao, Bhaskar N.

AU - Daw, Najat

AU - Rodriguez-Galindo, Carlos

AU - Hoffer, Fredric A.

AU - Stacy, G. Scott

AU - Peabody, Terrance D.

AU - Simon, Michael A.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The poor prognosis for patients with osteosarcoma skip metastases has been established in the literature; however, most of the data in the literature concerning osteosarcoma skip metastases were collected before routine use of magnetic resonance imaging and before the use of modern multiagent chemotherapy regimens. This retrospective multiinstitutional study was done to evaluate the efficacy of magnetic resonance imaging to detect skip metastases and to evaluate the prognosis for these patients when treated with modern multiagent chemotherapy protocols. In a group of 155 patients who were younger than 26 years when diagnosed and treated for high-grade osteosarcoma of the long bones, 10 (6.5%) patients with skip metastases were identified. Eight of the 10 lesions were detected on pretreatment magnetic resonance imaging scans and two were detected only from the surgical pathology specimens. Five patients had concomitant pulmonary metastases at presentation and five patients had no other known site of diseases. All 10 patients died, with an average survival of 32.5 months (range 11-71 months). The five patients with only skip metastases at presentation survived an average of 27.2 months (range 15-44 months). Despite advances in the treatment of patients with osteosarcomas, those with skip metastases continue to have a poor prognosis, and they should be counseled regarding the limitations of current therapies.

AB - The poor prognosis for patients with osteosarcoma skip metastases has been established in the literature; however, most of the data in the literature concerning osteosarcoma skip metastases were collected before routine use of magnetic resonance imaging and before the use of modern multiagent chemotherapy regimens. This retrospective multiinstitutional study was done to evaluate the efficacy of magnetic resonance imaging to detect skip metastases and to evaluate the prognosis for these patients when treated with modern multiagent chemotherapy protocols. In a group of 155 patients who were younger than 26 years when diagnosed and treated for high-grade osteosarcoma of the long bones, 10 (6.5%) patients with skip metastases were identified. Eight of the 10 lesions were detected on pretreatment magnetic resonance imaging scans and two were detected only from the surgical pathology specimens. Five patients had concomitant pulmonary metastases at presentation and five patients had no other known site of diseases. All 10 patients died, with an average survival of 32.5 months (range 11-71 months). The five patients with only skip metastases at presentation survived an average of 27.2 months (range 15-44 months). Despite advances in the treatment of patients with osteosarcomas, those with skip metastases continue to have a poor prognosis, and they should be counseled regarding the limitations of current therapies.

UR - http://www.scopus.com/inward/record.url?scp=4444320674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444320674&partnerID=8YFLogxK

U2 - 10.1097/01.blo.0000141493.52166.69

DO - 10.1097/01.blo.0000141493.52166.69

M3 - Article

SP - 92

EP - 96

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 426

ER -